Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)
ID: 350264Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/350264

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-297.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)." This initiative aims to identify innovative cure strategies for HIV that can be implemented at the initiation of combination antiretroviral therapy (cART) or upon restarting cART after treatment interruptions, with the ultimate goal of achieving sustained treatment-free remission. The program encourages interdisciplinary collaboration and participation from underrepresented groups, emphasizing the importance of advancing HIV cure research. Applications are due by December 7, 2023, and interested parties can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries. The funding is contingent on NIH appropriations, and proposals will be evaluated based on scientific merit and potential impact.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-297-Full-Announcement.html
    PAR-23-297.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Notice of Funding Opportunity (NOFO) titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation" (R01). This funding initiative aims to research new cure strategies for HIV that can be applied at the onset of combination antiretroviral therapy (cART) or upon restarting cART after treatment interruptions. The goal is to identify methods that lead to sustained treatment-free remission of HIV. Applications must adhere to strict guidelines and cannot involve clinical trials. Eligible applicants include various institutions such as higher education and nonprofit organizations, and all proposals will be evaluated based on scientific merit, significance, innovation, approach, and investigator qualifications. The review process will focus on the potential impact of the proposed research on the field of HIV treatment. Key dates include application submission deadlines starting December 7, 2023, with funding for meritorious projects contingent on NIH appropriations. This initiative emphasizes interdisciplinary collaboration and encourages participation from underrepresented groups to promote innovation and progress in HIV cure research.
    Similar Opportunities
    Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed)." This initiative aims to identify innovative cure strategies that can be implemented at the onset of combination antiretroviral therapy (cART) or upon restarting cART after an analytical treatment interruption, with the ultimate goal of achieving sustained treatment-free remission. The NIH encourages multidisciplinary research approaches that enhance understanding of HIV dynamics and improve strategies for sustained remission, while excluding clinical trials. Interested applicants, including a diverse range of institutions such as historically black colleges, tribal governments, and community-based organizations, must submit their proposals by September 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-297.html.
    Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Role of Defective Proviruses in HIV Persistence (R01 Clinical Trial Not Allowed)" aimed at supporting research on the impact of defective HIV proviruses on persistence and pathogenesis during antiretroviral treatment. The objective is to characterize these defective proviruses in human samples, optimize assays to mitigate their influence, and study their effects on viral dynamics, which is crucial for improving HIV cure strategies and understanding chronic immune activation in treated individuals. Eligible applicants include a wide range of institutions, such as public and private nonprofits, higher education entities, and for-profits, with funding available up to $500,000 per year for projects lasting a maximum of five years. Interested parties should note that applications can be submitted starting in April 2025, and all inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Innovation for HIV Vaccine Discovery" (NOFO Number PAR-23-169) aimed at supporting high-risk, high-impact early discovery research focused on innovative vaccine approaches to prevent HIV acquisition and ongoing infection. This initiative emphasizes a Go/No-Go funding approach, requiring applicants to demonstrate measurable progress towards defined goals by the end of Year 2, with continued funding contingent upon meeting these criteria. The overall budget for this initiative is approximately $2 million for fiscal year 2024, with individual project budgets capped at $350,000 per year, and applications must be submitted via Grants.gov by August 2, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Role of T-Cells in HIV CNS Reservoir Seeding, Persistence, and Neuropathogenesis (R01 Clinical Trial Not Allowed)" aimed at researching the mechanisms of T-cell involvement in HIV-related central nervous system (CNS) issues. This initiative seeks to develop therapeutic strategies that address T-cell neuro-invasion and HIV-associated neuroinflammation, with a focus on innovative and multidisciplinary approaches utilizing advanced technologies. Approximately $5.5 million is available for this research, with applications opening on February 17, 2025, and a submission deadline of March 18, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Planning for Product Development Strategy (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Planning for Product Development Strategy," aimed at supporting the development of comprehensive strategies for next-generation treatments and preventive methods for HIV and associated complications. The primary objective of this grant is to facilitate the planning activities necessary for submitting an Investigational New Drug (IND) application to the FDA, with a focus on translating innovative research into effective drug products. This funding opportunity is particularly significant as it encourages collaboration among multidisciplinary teams to address critical health challenges related to HIV. Interested applicants can apply starting February 13, 2024, with a total funding amount of $1,000,000 anticipated for 2-3 awards in fiscal year 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-029.html.
    Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt) (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Translation of Long-Acting Strategies for HIV and HIV-Associated Co-infections (AT LASt)" aimed at supporting the development of long-acting/sustained release (LA/SR) technologies for the prevention and treatment of HIV and associated co-infections such as tuberculosis (TB), hepatitis B (HBV), and hepatitis C (HCV). This initiative seeks to fund preclinical activities that will advance these technologies toward submission of Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA), with a focus on ensuring safety and efficacy through rigorous studies. The program is particularly significant as it addresses public health challenges related to infectious diseases that disproportionately affect individuals living with HIV, and it will provide approximately $4 million to support 3-5 awards, with applications due by March 14, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research to enhance the integration of HIV, addiction, and primary care services. This initiative invites applications for R34 Planning Grants to develop and test models that improve healthcare delivery for individuals at risk for or living with HIV, Hepatitis B and C, and substance use disorders, with a focus on strategies such as integrating substance misuse prevention within HIV care settings. The total funding available for this project is $2 million, with awards potentially lasting up to three years, and applications are due by March 20, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 Clinical Trial optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services," aimed at supporting innovative research in integrated care models for HIV/AIDS and substance use disorders. The initiative seeks to improve health outcomes and enhance care coordination for individuals at heightened risk by addressing service delivery gaps through collaborative and evidence-based practices. This grant, with a funding ceiling of $450,000 over three years, is open to a diverse range of eligible applicants, including higher education institutions and community-based organizations, with applications due by March 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-020.html.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the R21 Exploratory/Developmental Research Grant under the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes." This initiative aims to support innovative research that enhances HIV prevention and care strategies by exploring behavioral and social science approaches, new intervention methods, and implementation science, particularly addressing gaps in engagement, adherence, and retention in healthcare services. The grant, with a funding ceiling of $275,000 over two years, emphasizes collaboration with community organizations and the inclusion of diverse populations, aligning with national and global health objectives. Interested applicants can submit their proposals until January 9, 2026, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional)" under the National Institute of Mental Health (NIMH). This initiative aims to support innovative research focused on optimizing HIV prevention and care, emphasizing the understanding of behavioral and social science factors that influence the HIV continuum, including intervention efficacy trials and implementation science studies. The program is critical for advancing national efforts to address HIV effectively, promoting community engagement and multidisciplinary collaboration to achieve equitable health outcomes for diverse populations. Interested applicants can find more information and application details at the provided link, with a submission deadline of January 9, 2026, and no cost-sharing or matching requirements.